Novo Nordisk has announced a major restructuring initiative aiming to refocus on its core diabetes and obesity markets amid heightened competition and slowing growth in obesity drugs. The Danish pharmaceutical giant plans to cut approximately 9,000 jobs, representing an 11% workforce reduction. Concurrently, Novo Nordisk has mandated a full-time return to office policy to enhance collaboration and decision-making efficiency under the new CEO’s leadership. These moves follow a significant share price decline and a nearly $450 billion market cap reduction in the past year due to pressure from Eli Lilly and copycat drugs.